Daniel Bertin, Jehanne Aghzadi, Nathalie Balandraud, Céline Roman, Mélanie Serrero, Sophie Desplat-Jégo
{"title":"Detection of Antibodies to Infliximab in routine care: a 4-year French retrospective study.","authors":"Daniel Bertin, Jehanne Aghzadi, Nathalie Balandraud, Céline Roman, Mélanie Serrero, Sophie Desplat-Jégo","doi":"10.1093/cei/uxae122","DOIUrl":null,"url":null,"abstract":"<p><p>Despite its wide use to treat various inflammatory diseases, infliximab becomes ineffective in some patients due to inadequate drug levels and production of anti-drug antibodies (ADA). The aim of this study was to compare the prevalence and ADA levels in a large cohort of patients ADA and IFX through levels measured by ELISA were collected from 505 patients within a period of four years. The results indicate that i) 13.5% of patients produce ADA, ii) male patients were more likely to produce ADA at levels above 10000 ng/mL than female patients, iii) ADA levels were lower when associated with immunosuppressant drugs, iv) there was an inverse relationship between ADA presence and IFX detection, v) no correlation was observed between ADA levels and number of injections or brand of IFX administered. This study improves our understanding of the factors promoting IFX immunogenicity and highlights the need to develop personalized treatment strategies.</p>","PeriodicalId":10268,"journal":{"name":"Clinical and experimental immunology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cei/uxae122","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Despite its wide use to treat various inflammatory diseases, infliximab becomes ineffective in some patients due to inadequate drug levels and production of anti-drug antibodies (ADA). The aim of this study was to compare the prevalence and ADA levels in a large cohort of patients ADA and IFX through levels measured by ELISA were collected from 505 patients within a period of four years. The results indicate that i) 13.5% of patients produce ADA, ii) male patients were more likely to produce ADA at levels above 10000 ng/mL than female patients, iii) ADA levels were lower when associated with immunosuppressant drugs, iv) there was an inverse relationship between ADA presence and IFX detection, v) no correlation was observed between ADA levels and number of injections or brand of IFX administered. This study improves our understanding of the factors promoting IFX immunogenicity and highlights the need to develop personalized treatment strategies.
期刊介绍：
Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice.
The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
